AKBA
BEARISH
$1.46
Live
Akebia Therapeutics, Inc. · NASDAQ
Target $4.4
(+201.4%)
$1.14
52W Range
$4.08
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$391.1M
P/E
N/A
ROE
N/A
Profit margin
-2.3%
Debt/Equity
6.1
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AKBA's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, while the absence of an Altman Z-Score raises bankruptcy risk concerns. Despite strong revenue growth (23.9% YoY) and a high gross margin (82.92%), the company operates at a net loss with negative profit and operating margins, and carries a dangerously high debt/equity ratio of 6.10. Insider selling activity totaling $0.90M over six months, including large sales by executives and the CEO, reinforces bearish sentiment. The stock trades at a premium valuation (Price/Sales: 1.66, Price/Book: 11.87) despite negative earnings and no intrinsic value support, making it vulnerable to downside pressure.
Key Strengths
Strong revenue growth of 23.9% YoY
High gross margin of 82.92% indicates pricing power or low production costs
Positive recent quarterly earnings surprises (average +53.7% over last 4 quarters)
Analyst consensus of 'strong_buy' with a target price of $4.40 (up 200% from current)
Significant 1-week price rebound (+15.0%) suggests short-term momentum
Key Risks
Piotroski F-Score of 2/9 indicates severe financial and operational weakness
Debt/Equity ratio of 6.10 is extremely high, signaling financial leverage risk
Negative net profit margin (-2.26%) and operating margin (-10.50%) despite revenue growth
Insider selling by multiple executives and CEO totaling $0.90M in last 6 months
No available cash flow, FCF, or ROE data, indicating lack of financial transparency and sustainability
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
31
Weak
30
65
40
20
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (2/9), High debt/equity (6.10), Negative profitability, Insider selling, No available cash flow or ROE metrics
Confidence
85%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 1.66 is below sector average (137.63% revenue growth) but not low for a loss-making firm
- Target price of $4.40 implies strong upside potential
Watchpoints
- No Graham Number or intrinsic value due to negative earnings and no stable cash flow
- Price/Book of 11.87 is extremely high for a company with negative ROE and losses
- Trading at premium despite lack of profitability and high leverage
Future
65/100
Ref Growth rates
Positives
- 23.9% YoY revenue growth suggests market expansion or product demand
- Recent earnings surprises (avg +53.7%) indicate potential for better-than-expected results
- Analyst target price implies strong growth expectations
Watchpoints
- Forward P/E of -15.37 reflects continued losses
- Negative earnings growth (-25.0% YoY) despite revenue growth
- No free cash flow or operating cash flow data to validate sustainability
Past
40/100
Ref Historical trends
Positives
- Historical earnings surprises have been volatile but occasionally large (e.g., +161.8%, +169.0%)
- Revenue growth has been consistently positive over multiple quarters
Watchpoints
- Frequent negative earnings surprises (e.g., -138.3%, -141.2%)
- Persistent net losses and declining profitability trends
- Q/Q EPS growth of -350.0% indicates worsening earnings quality
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.55 and quick ratio of 1.42 suggest short-term liquidity is adequate
Watchpoints
- Piotroski F-Score of 2/9 is critically low, indicating poor financial health
- No Altman Z-Score available, but debt/equity of 6.10 exceeds typical safe thresholds
- Negative ROA (5.44%) is misleading due to lack of context; likely distorted by non-recurring items
- No available ROIC or FCF data to assess capital efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength: 0/100
- Company is not generating profits to support dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.46
Analyst Target
$4.4
Upside/Downside
+201.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AKBA and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
Primary
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
NRC
National Research Corporation
Peer
|
-58.9% | -57.9% | +63.5% | +50.6% | -1.2% | 0.0% |
|
ENTA
Enanta Pharmaceuticals, Inc.
Peer
|
-71.8% | -64.9% | +208.7% | +21.9% | -0.9% | +6.2% |
|
IRD
Opus Genetics, Inc.
Peer
|
+2.3% | -0.9% | +654.9% | +173.5% | +7.0% | +17.8% |
|
KIDS
OrthoPediatrics Corp.
Peer
|
-67.6% | -67.3% | -25.3% | -2.0% | -10.3% | -0.6% |
AKB
Akebia Therapeutics, Inc.
Primary
5Y
-59.4%
3Y
+113.8%
1Y
-13.6%
6M
-50.5%
1M
-5.8%
1W
+15.0%
NRC
National Research Corporation
Peer
5Y
-58.9%
3Y
-57.9%
1Y
+63.5%
6M
+50.6%
1M
-1.2%
1W
0.0%
ENT
Enanta Pharmaceuticals, Inc.
Peer
5Y
-71.8%
3Y
-64.9%
1Y
+208.7%
6M
+21.9%
1M
-0.9%
1W
+6.2%
IRD
Opus Genetics, Inc.
Peer
5Y
+2.3%
3Y
-0.9%
1Y
+654.9%
6M
+173.5%
1M
+7.0%
1W
+17.8%
KID
OrthoPediatrics Corp.
Peer
5Y
-67.6%
3Y
-67.3%
1Y
-25.3%
6M
-2.0%
1M
-10.3%
1W
-0.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-15.37
PEG Ratio
N/A
P/B Ratio
11.87
P/S Ratio
1.66
EV/Revenue
1.72
EV/EBITDA
14.85
Market Cap
$391.1M
Profitability
Profit margins and return metrics
Profit Margin
-2.26%
Operating Margin
-10.5%
Gross Margin
82.92%
ROE
N/A
ROA
5.44%
Growth
Revenue and earnings growth rates
Revenue Growth
+23.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
6.1
High debt
Current Ratio
1.55
Good
Quick Ratio
1.42
Good
Cash/Share
$0.69
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
78.2%
Op. Margin
-14.8%
Net Margin
-21.2%
Total Assets
$0.4B
Liabilities
$0.3B
Equity
$0.0B
Debt/Equity
10.55x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
75%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$-0.05
-38.9% surprise
2025-11-10
$N/A
+100.0% surprise
2025-08-07
$N/A
+100.0% surprise
Healthcare Sector Comparison
Comparing AKBA against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Profit Margin
-2.26%
This Stock
vs
-12.47%
Sector Avg
-81.9%
(Weaker)
Debt to Equity
6.1
This Stock
vs
3.4
Sector Avg
+79.2%
(Higher)
Revenue Growth
23.9%
This Stock
vs
124.21%
Sector Avg
-80.8%
(Slower)
Current Ratio
1.55
This Stock
vs
4.56
Sector Avg
-66.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | |
|
NRC
National Research Corporation
|
BEARISH | $387.6M | 34.08 | 51.2% | 8.4% | $17.04 | Compare |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
BEARISH | $399.6M | - | -60.0% | -106.8% | $13.77 | Compare |
|
IRD
Opus Genetics, Inc.
|
BEARISH | $381.36M | - | -242.4% | -% | $5.36 | Compare |
|
KIDS
OrthoPediatrics Corp.
|
BEARISH | $403.7M | - | -11.3% | -16.8% | $15.97 | Compare |
AKBA
Akebia Therapeutics, Inc.
BEARISH
Mkt Cap
$391M
P/E
-
ROE
-%
Price
$1.46
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | BUTLER JOHN P | Chief Executive Officer | Purchase | 69,270 | $86,588 |
| 2026-02-02 | BURKE STEVEN KEITH | Officer | Sale | 67,658 | $94,045 |
| 2026-02-02 | BUTLER JOHN P | Chief Executive Officer | Sale | 341,305 | $474,414 |
| 2026-02-02 | GRUND NICHOLAS | Officer | Sale | 84,829 | $117,912 |
| 2026-02-02 | OSTROWSKI ERIK | Chairman of the Board | Sale | 34,951 | $48,582 |
| 2026-02-02 | MALABRE RICHARD C. | Officer | Sale | 49,524 | $68,838 |
| 2026-02-02 | RUCCI CAROLYN M | Officer | Sale | 69,772 | $96,983 |
| 2026-02-02 | BUTLER JOHN P | Chief Executive Officer | Stock Award | 175,250 | $247,102 |
| 2026-01-30 | BURKE STEVEN KEITH | Officer | Stock Award | 204,000 | - |
| 2026-01-30 | BUTLER JOHN P | Chief Executive Officer | Stock Award | 743,000 | - |
| 2026-01-30 | GRUND NICHOLAS | Officer | Stock Award | 204,000 | - |
| 2026-01-30 | OSTROWSKI ERIK | Chairman of the Board | Stock Award | 204,000 | - |
| 2026-01-30 | MALABRE RICHARD C. | Officer | Stock Award | 79,000 | - |
| 2026-01-30 | RUCCI CAROLYN M | Officer | Stock Award | 190,000 | - |
BUTLER JOHN P
Chief Executive Officer
2026-03-04
69,270 shares
·
$86,588
BURKE STEVEN KEITH
Officer
2026-02-02
67,658 shares
·
$94,045
BUTLER JOHN P
Chief Executive Officer
2026-02-02
341,305 shares
·
$474,414
GRUND NICHOLAS
Officer
2026-02-02
84,829 shares
·
$117,912
OSTROWSKI ERIK
Chairman of the Board
2026-02-02
34,951 shares
·
$48,582
MALABRE RICHARD C.
Officer
2026-02-02
49,524 shares
·
$68,838
RUCCI CAROLYN M
Officer
2026-02-02
69,772 shares
·
$96,983
BUTLER JOHN P
Chief Executive Officer
2026-02-02
175,250 shares
·
$247,102
BURKE STEVEN KEITH
Officer
2026-01-30
204,000 shares
BUTLER JOHN P
Chief Executive Officer
2026-01-30
743,000 shares
GRUND NICHOLAS
Officer
2026-01-30
204,000 shares
OSTROWSKI ERIK
Chairman of the Board
2026-01-30
204,000 shares
MALABRE RICHARD C.
Officer
2026-01-30
79,000 shares
RUCCI CAROLYN M
Officer
2026-01-30
190,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
5 analysts
BTIG
2026-02-25
Buy
Buy
Piper Sandler
2026-02-06
Overweight
Overweight
HC Wainwright & Co.
2026-02-06
Buy
Buy
BTIG
2025-12-02
Buy
Buy
HC Wainwright & Co.
2025-12-02
Buy
Buy
HC Wainwright & Co.
2025-10-30
Buy
Buy
BTIG
2025-10-29
Buy
Buy
Past News Coverage
Recent headlines mentioning AKBA from our newsroom.
Newest → oldest
No matching news yet.